CT103A
- Generic Name
- CT103A
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
CT103A is an investigational BCMA-targeted genetically modified autologous T-cell immunotherapy.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2022-05-24
- Lead Sponsor
- Chunrui Li
- Target Recruit Count
- 20
- Registration Number
- NCT05201118
- Locations
- 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hu Bei, China
A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
- Target Recruit Count
- 132
- Registration Number
- NCT05066646
- Locations
- 🇨🇳
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
🇨🇳Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
🇨🇳The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath